Early benefit assessment of medications

The price of new drugs in Germany depends on the result of the so-called early benefit assessment. The legal basis for this is the “Act on the Reform of the Market for Medicinal Products (AMNOG).” Here you can find information on medications that have been assessed by the German Institute for Quality and Efficiency in Health Care (IQWiG, Germany) in the last few years.

Early benefit assessment of medications from A to Z

Popular in Early benefit assessment of medications

  • Drugs assessed by IQWiG

    Drugs assessed by IQWiG

    Since early 2011, the added benefit of most medications containing new active ingredients must be assessed as soon as they enter the market in German...

  • Dulaglutide (Trulicity) for the treatment of type 2 diabetes

    Dulaglutide (Trulicity) for the treatment of type 2 diabetes

    Dulaglutide (trade name: Trulicity) has been approved in Germany since November 2014 for the treatment of type 2 diabetes when diet and exercise alon...